Mechanistic description
TREM2 agonism enhances microglial phagocytosis of α-synuclein aggregates via DAP12 signaling. Alector AL002 anti-TREM2 antibody in Phase II represents clinical validation, but temporal dynamics, species divergence, and biomarker gaps remain critical challenges for translation.
Mechanism / pathway
- TREM2
- neurodegeneration
Evidence for (3)
TREM2 R47H variant associates with increased AD risk; PD association weaker but present
TREM2-dependent microglial states observed in α-syn PFF mouse models
AL002 anti-TREM2 antibody entering Phase II (Alector)
Evidence against (3)
Conditional TREM2 knockout in some models shows preserved aggregate clearance
Murine TREM2 biology diverges from human in ligand recognition
Optimal intervention window undefined across disease stages
Evidence matrix
Supporting
- TREM2 R47H variant associates with increased AD risk; PD association weaker but present PMID:30642943
- TREM2-dependent microglial states observed in α-syn PFF mouse models PMID:30867421
- AL002 anti-TREM2 antibody entering Phase II (Alector) PMID:clinicaltrials.gov-NCT04557366
Contradicting
- Conditional TREM2 knockout in some models shows preserved aggregate clearance PMID:29909903
- Murine TREM2 biology diverges from human in ligand recognition PMID:30250057
- Optimal intervention window undefined across disease stages PMID:31430419
Cite this hypothesis
Cite this hypothesis
envelope-repair (2026). TREM2 Microglial Agonism for Enhanced Phagocytosis. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-869b5707e8
@misc{scidex_hypothesis_h869b570,
title = {TREM2 Microglial Agonism for Enhanced Phagocytosis},
author = {envelope-repair},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-869b5707e8},
note = {SciDEX artifact hypothesis:h-869b5707e8}
}